Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Raised by Bronte Capital Management Pty Ltd.

Bronte Capital Management Pty Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 152,783 shares of the biopharmaceutical company's stock after purchasing an additional 15,741 shares during the quarter. Regeneron Pharmaceuticals comprises 15.8% of Bronte Capital Management Pty Ltd.'s portfolio, making the stock its 3rd largest position. Bronte Capital Management Pty Ltd. owned approximately 0.14% of Regeneron Pharmaceuticals worth $108,832,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in REGN. Mizuho Securities USA LLC increased its position in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after acquiring an additional 51,162 shares in the last quarter. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock worth $10,082,000 after purchasing an additional 3,231 shares during the period. Golden State Equity Partners grew its position in Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 1,272 shares during the period. Finally, Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Sanford C. Bernstein dropped their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Finally, Bank of America reiterated an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $718.16 on Wednesday. The company has a market capitalization of $78.51 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm's 50-day moving average is $697.08 and its 200 day moving average is $842.19.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.